A Literature Review of Pulmonary Arterial Hypertension (PAH)

被引:1
作者
Panchal, Ashima [1 ]
Panchal, Jigar [2 ]
Jain, Sonika [2 ]
Dwivedi, Jaya [2 ]
机构
[1] Cent Univ Punjab, Dept Chem, Ghudda, Punjab, India
[2] Banasthali Vidyapith, Dept Chem, Banasthali 304022, India
关键词
Pulmonary arterial hypertension (PAH); Pulmonary capillary wedge pressure (PCWP); pathology; pathogenesis; endothelin; blood pressure; INHALED ILOPROST; BOSENTAN THERAPY; PROSTACYCLIN; MUTATIONS; SEROTONIN; RIOCIGUAT; ACETYLCHOLINE; ENDOTHELIN-1; EPOPROSTENOL; AMBRISENTAN;
D O I
10.2174/1573398X18666220217151152
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
In 1891, German doctor E. Romberg was the first to report PAH. It is widespread throughout the world, but it is particularly problematic in India and other developing countries. Pulmonary arterial hypertension (PAH) is characterised by an increase in pulmonary arterial pressure as well as the emergence of progressive symptoms, such as a loss of functional ability, shortness of breath, and fatigue. Blood flows from the right side of the heart to the lungs through the pulmonary arteries. Pulmonary arterial pressure refers to the pressure in the arteries of the lungs (PAH). It necessitates immediate treatment because high blood pressure in the lungs causes the right side of the heart to work much harder, increasing the risk of heart failure. This article aimed to provide brief information about the prevalence, pathology, classification, and different therapies of PAH.
引用
收藏
页码:104 / 114
页数:11
相关论文
共 67 条
  • [1] [Anonymous], 1975, PRIM PULM HYP REP WH
  • [2] Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry
    Badesch, David B.
    Raskob, Gary E.
    Elliott, C. Greg
    Krichman, Abby M.
    Farber, Harrison W.
    Frost, Adaani E.
    Barst, Robyn. J.
    Benza, Raymond L.
    Liou, Theodore G.
    Turner, Michelle
    Giles, Scott
    Feldkircher, Kathy
    Miller, Dave P.
    McGoon, Michael D.
    [J]. CHEST, 2010, 137 (02) : 376 - 387
  • [3] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
    Barst, RJ
    Rubin, LJ
    Long, WA
    McGoon, MD
    Rich, S
    Badesch, DB
    Groves, BM
    Tapson, VF
    Bourge, RC
    Brundage, BH
    Koerner, SK
    Langleben, D
    Keller, CA
    Murali, S
    Uretsky, BF
    Clayton, LM
    Jobsis, MM
    Blackburn, SD
    Shortino, D
    Crow, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) : 296 - 301
  • [4] Chaumais MC, 2013, HANDB EXP PHARMACOL, V218, P161, DOI 10.1007/978-3-642-38664-0_7
  • [5] Pulmonary arterial hypertension: Advances in pathophysiology and management
    Chopra, Sandeep
    Badyal, Dinesh K.
    Baby, Chris P.
    Cherian, Davis
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2012, 44 (01) : 4 - 11
  • [6] AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION
    CHRISTMAN, BW
    MCPHERSON, CD
    NEWMAN, JH
    KING, GA
    BERNARD, GR
    GROVES, BM
    LOYD, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) : 70 - 75
  • [7] THE ENDOTHELIN ET(B) RECEPTOR MEDIATES BOTH VASODILATION AND VASOCONSTRICTION INVIVO
    CLOZEL, M
    GRAY, GA
    BREU, V
    LOFFLER, BM
    OSTERWALDER, R
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (02) : 867 - 873
  • [8] Bosentan therapy for pulmonary arterial hypertension
    Cohen, H
    Chahine, C
    Hui, A
    Mukherji, R
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (11) : 1107 - 1119
  • [9] ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells
    Davie, N
    Haleen, SJ
    Upton, PD
    Polak, JM
    Yacoub, MH
    Morrell, NW
    Wharton, J
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (03) : 398 - 405
  • [10] Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650